Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 9
2014 26
2015 31
2016 24
2017 24
2018 33
2019 32
2020 36
2021 30
2022 25
2023 26
2024 5

Text availability

Article attribute

Article type

Publication date

Cited In for PMID: 23769296

274 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; PSUMMIT 1 Study Group. McInnes IB, et al. Lancet. 2013 Aug 31;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13. Lancet. 2013. PMID: 23769296 Clinical Trial.
Treatment of non-systemic juvenile idiopathic arthritis.
Shenoi S, Horneff G, Aggarwal A, Ravelli A. Shenoi S, et al. Nat Rev Rheumatol. 2024 Mar;20(3):170-181. doi: 10.1038/s41584-024-01079-8. Epub 2024 Feb 6. Nat Rev Rheumatol. 2024. PMID: 38321298 Review.
Choosing Therapies in Ulcerative Colitis.
Das R, Steinhart AH. Das R, et al. J Can Assoc Gastroenterol. 2023 Sep 4;7(1):9-21. doi: 10.1093/jcag/gwad025. eCollection 2024 Feb. J Can Assoc Gastroenterol. 2023. PMID: 38314181 Free PMC article.
Guselkumab, a Novel Monoclonal Antibody Inhibitor of the p19 Subunit of IL-23, for Psoriatic Arthritis and Plaque Psoriasis: A Review of Its Mechanism, Use, and Clinical Effectiveness.
Kerut CK, Wagner MJ, Daniel CP, Fisher C, Henderson EJ, Burroughs CR, Amarasinghe S, Willett O, Ahmadzadeh S, Varrassi G, Shekoohi S, Kaye AD. Kerut CK, et al. Cureus. 2023 Dec 31;15(12):e51405. doi: 10.7759/cureus.51405. eCollection 2023 Dec. Cureus. 2023. PMID: 38292958 Free PMC article. Review.
Signaling pathways and targeted therapies for psoriasis.
Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Guo J, et al. Signal Transduct Target Ther. 2023 Nov 27;8(1):437. doi: 10.1038/s41392-023-01655-6. Signal Transduct Target Ther. 2023. PMID: 38008779 Free PMC article. Review.
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.
Papp KA, Lebwohl MG, Thaçi D, Jaworski J, Kwiek B, Trefler J, Dudek A, Szepietowski JC, Reznichenko N, Narbutt J, Baran W, Kolinek J, Daniluk S, Bartnicka-Maslowska K, Reich A, Andrashko Y, Kim S, Bae Y, Jeon D, Jung J, Lee H, Pyo T, Ko W. Papp KA, et al. BioDrugs. 2024 Jan;38(1):121-131. doi: 10.1007/s40259-023-00630-5. Epub 2023 Nov 22. BioDrugs. 2024. PMID: 37991693 Free PMC article. Clinical Trial.
274 results